lnterleukin-5 (IL-5) is a member of the short chain subfamily of the helical bundle family of cytokines. IL-5 signals through a heterodimeric receptor, IL-5R-alpha/IL-5R-beta, inducing pleotrophic effects on a number of leukocytes. Physiologically IL-5 aids in host defense against parasites and tumors while its dysregulation has been associated with asthma and allergic disease. Thus, IL-5 and its receptor are obvious targets for modulation of such inflammatory responses. The goal of this application is to understand the molecular interactions between IL-5 and its receptor subunits. Toward this goal, we have successfully modeled and expressed the first IL-5 monomer with biologic activity (designated mono5), thereby demonstrating that all the structural features necessary for IL-5 function are contained within a single helical bundle. In addition, a panel of anti-IL-5 neutralizing mAb, COS-7 expressed interspecies IL-5 chimeras, and molecular modeling have been used to localize five neutralizing epitopes and the species specificity residues of IL-5 within two domains.
The specific aims are proposed to: 1) test our hypothesis that mono5 serves as a paradigm for investigating whether homodimerization of native IL-5 is biologically advantageous or is a novel biologic mechanism for conservation of an essential functional motif within the helical bundle family of cytokines; and 2) define the precise structural requirements for engagement of IL-5 and its receptor.
Aim I will determine whether a homodimeric IL-5 configuration imparts a functional advantage over a monomeric helical bundle for receptor binding. Native IL-5 and mono5 will be studied for differences in receptor ligand binding kinetics. In addition, a loop 3 deletion mutant of the monomeric cytokine GM-CSF will be generated and analyzed for the predicted formation of an interdigitating homodimer with enhanced biological activity.
Aim II will test the hypothesis that residues proximate to the junction of loop 3 and helix D of IL-5 engage the IL-5R-alpha chain. Predicted residues will be assessed by defining the confirmational epitopes and bioactivity of IL-5 mutants generated by site-directed mutagenesis.
Aim III will test the hypothesis that residues proximate to loop 2 and the middle of helix A of IL-5 engage the IL-5R-beta chain, utilizing site-directed mutagenesis of COS-7 expressed IL-5. The structure/function analyses of IL-5 signaling should enable the development of IL-5 analogs capable of antagonizing IL-5-mediated inflammation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI036936-04
Application #
2886960
Study Section
Allergy and Immunology Study Section (ALY)
Program Officer
Plaut, Marshall
Project Start
1996-07-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2001-06-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Amini-Vaughan, Zhaleh J; Martinez-Moczygemba, Margarita; Huston, David P (2012) Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer. Curr Allergy Asthma Rep 12:402-12
Martinez-Moczygemba, Margarita; Huston, David P (2010) Immune dysregulation in the pathogenesis of pulmonary alveolar proteinosis. Curr Allergy Asthma Rep 10:320-5
Martinez-Moczygemba, Margarita; Doan, Minh L; Elidemir, Okan et al. (2008) Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 205:2711-6
Martinez-Moczygemba, Margarita; Huston, David P; Lei, Jonathan T (2007) JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization. J Leukoc Biol 81:1137-48
Ng, Bernard; Yang, Fan; Huston, David P et al. (2004) Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 114:1463-70
Martinez-Moczygemba, Margarita; Huston, David P (2003) Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 112:653-65; quiz 666
Martinez-Moczygemba, M; Huston, D P (2001) Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization. J Clin Invest 108:1797-806
Huston, D P; Huston, M M; Dickason, R R et al. (2000) Interleukin-5, a therapeutic target in allergic inflammation. Trans Am Clin Climatol Assoc 111:46-59; discussion 59-60
Bressler, R B; Lesko, J; Jones, M L et al. (1997) Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligation. J Allergy Clin Immunol 99:508-14
Dickason, R R; English, J D; Huston, D P (1996) Engineering of a functional interleukin-5 monomer: a paradigm for redesigning helical bundle cytokines with therapeutic potential in allergy and asthma. J Mol Med 74:535-46